-
The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes
-
Xingen Wang, Julia Y. S. Tsang, Michelle A Lee, Yun-Bi Ni, Joanna H Tong, Siu-Ki Chan, Sai-Yin Cheung, Ka Fai To, Gary M Tse
-
Cancer Res Treat. 2019;51(2):706-717. Published online August 23, 2018
-
DOI: https://doi.org/10.4143/crt.2018.316
-
-
 Abstract
 PDF Supplementary Material PubReader ePub
- Purpose
Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a novel nuclear receptor (NR) co-regulator, is highly expressed in breast cancer. We investigated its expression in breast cancer subtypes, in comparison with other breast markers as well as cancers from different sites. Its prognostic relevance with different subtypes and other NR expression was also examined in breast cancers.
Methods
Immunohistochemical analysis was performed on totally 1,944 cancers from six different organs.
Results
PELP1 expression rate was the highest in breast cancers (70.5%) among different cancers. Compared to GATA3, mammaglobin and gross cystic disease fluid protein 15, PELP1 was less sensitive than GATA3 for luminal cancers, but was the most sensitive for non-luminal cancers. PELP1 has low expression rate (<20%) in colorectal cancers, gastric cancers and renal cell carcinomas, but higher in lung cancers (49.1%) and ovarian cancers (42.3%). In breast cancer, PELP1 expression was an independent adverse prognostic factor for non-luminal cancers (disease-free survival [DFS]: hazard ratio [HR], 1.403; p=0.012 and breast cancer specific survival [BCSS]: HR, 1.443; p=0.015). Interestingly, its expression affected the prognostication of androgen receptor (AR). ARposPELP1lo luminal cancer showed the best DFS (log-rank=8.563, p=0.036) while ARnegPELP1hi non-luminal cancers showed the worst DFS (log-rank=9.536, p=0.023).
Conclusion
PELP1 is a sensitive marker for breast cancer, particularly non-luminal cases. However, its considerable expression in lung and ovarian cancers may limit its utility in differential diagnosis in some scenarios. PELP1 expression was associated with poor outcome in non-luminal cancers and modified the prognostic effects of AR, suggesting the potential significance of NR co-regulator in prognostication.
-
Citations
Citations to this article as recorded by  - Trichorhinophalangeal Syndrome Type 1 Is a Highly Sensitive and Specific Marker for Diagnosing Triple-Negative Breast Carcinomas on Cytologic Samples
Terrance J. Lynn, Jianhui Shi, Haiyan Liu, Sara E. Monaco, Jeffrey W. Prichard, Fan Lin
Archives of Pathology & Laboratory Medicine.2024; 148(1): e1. CrossRef - Value of Proline, Glutamic Acid, and Leucine-Rich Protein 1 and GATA Binding Protein 3 Expression in Breast Cancer: An Immunohistochemical study
Manar Moustafa, Magdy Ismael, Salah Mohamed, Abeer M. Hafez
Indian Journal of Surgery.2023; 85(3): 608. CrossRef - MiR-195-5p is involved in testicular ischemia/reperfusion injury by directly targeting PELP1 and regulating spermatogonia pyroptosis
KAI-XIANG HE, LIZHE XU, JIN-ZHUO NING, FAN CHENG
International Immunopharmacology.2023; 121: 110427. CrossRef - Estrogen Receptor Signaling in Breast Cancer
Paulina Miziak, Marzena Baran, Ewa Błaszczak, Alicja Przybyszewska-Podstawka, Joanna Kałafut, Jolanta Smok-Kalwat, Magdalena Dmoszyńska-Graniczka, Michał Kiełbus, Andrzej Stepulak
Cancers.2023; 15(19): 4689. CrossRef - Immunohistochemical study of proline, glutamic acid and leucine-rich protein 1 (PELP1) in correlation with guanine adenine thymine adenine family member 3 (GATA-3) receptors expression in breast carcinomas
Ahmed A Elmetwally, Mennat Allah M Abdel-Hafeez, Makram M Hammam, Gamal A Hafez, Maha M Atwa, Mohammed K El-Kherbetawy
Egyptian Journal of Pathology.2023; 43(1): 53. CrossRef - Diagnostic utility of PELP1 and GATA3 in primary and metastatic triple negative breast cancer
Manar Moustafa, Magdy Ismael, Salah Mohamed, Abeer Magdy
Revista de Senología y Patología Mamaria.2022; 35(3): 153. CrossRef - Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit
Qingqing Ding, Lei Huo, Yan Peng, Esther C. Yoon, Zaibo Li, Aysegul A. Sahin
Seminars in Diagnostic Pathology.2022; 39(5): 313. CrossRef - PELP1 is overexpressed in lung cancer and promotes tumor cell malignancy and resistance to tyrosine kinase inhibitor drug
Xingen Wang, Weihua Yin, Li Liang
Pathology - Research and Practice.2022; 237: 154065. CrossRef - Overexpression of PELP1 in Lung Adenocarcinoma Promoted E2 Induced Proliferation, Migration and Invasion of the Tumor Cells and Predicted a Worse Outcome of the Patients
Dongmei Zhang, Jiali Dai, Yu Pan, Xiuli Wang, Juanjuan Qiao, Hironobu Sasano, Baoshan Zhao, Keely M. McNamara, Xue Guan, Lili Liu, Yanzhi Zhang, Monica S. M. Chan, Shuwen Cao, Ming Liu, Sihang Song, Lin Wang
Pathology and Oncology Research.2021;[Epub] CrossRef - PELP1 Suppression Inhibits Gastric Cancer Through Downregulation of c-Src-PI3K-ERK Pathway
Hongzhu Yan, Yanling Sun, Qian Wu, Zhe Wu, Meichun Hu, Yuanpeng Sun, Yusi Liu, Zi Ma, Shangqin Liu, Wuhan Xiao, Fuxing Liu, Zhifeng Ning
Frontiers in Oncology.2020;[Epub] CrossRef
-
7,680
View
-
165
Download
-
10
Web of Science
-
10
Crossref
|
KCA
